- Home
- BYSI
BYSI
BeyondSpring Inc.
as 10-09-2025 3:51pm EST
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 73.4M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 35.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $3.44 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of BeyondSpring Inc. (BYSI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 7 '25 | Sell | $1.79 | 2,100 | $3,759.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 6 '25 | Sell | $1.78 | 17,500 | $31,150.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 3 '25 | Sell | $1.76 | 600 | $1,056.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 2 '25 | Sell | $1.73 | 600 | $1,038.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 1 '25 | Sell | $1.80 | 2,601 | $4,681.80 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 30 '25 | Sell | $1.81 | 4,464 | $8,079.84 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 29 '25 | Sell | $1.75 | 500 | $875.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 26 '25 | Sell | $1.68 | 600 | $1,008.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 25 '25 | Sell | $1.66 | 700 | $1,162.00 | 1,817,896 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 24 '25 | Sell | $1.68 | 2,256 | $3,790.08 | 1,817,896 |
Latest BeyondSpring Inc. News
BYSI Breaking Stock News: Dive into BYSI Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 months ago
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
GlobeNewswire
4 months ago
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
Simply Wall St.
5 months ago
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
GlobeNewswire
5 months ago
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
6 months ago
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewswire
6 months ago
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
GlobeNewswire
8 months ago
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
GlobeNewswire
8 months ago
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
Compare BYSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BYSI BeyondSpring Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.